HIV/AIDS has long been a global public health concern, with 1.2 million individuals in the United States living with the disease. However, adherence to daily medication regimens has posed challenges, leading to treatment interruptions and suboptimal outcomes for many patients.
“The once-weekly oral regimen offers the potential to simplify HIV care and address challenges related to daily medication adherence and pill-fatigue,” said Dr. Ronald G. Nahass, president of ID Care and co-author of the study.
Dr. Nahass emphasizes the significance of this discovery in simplifying HIV care. While HIV treatment should ideally be lifelong, statistics show that 32% of patients discontinue treatment within the first three years.
The study’s findings, presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) and reported in the Associated Press, offer hope for improving the lives of individuals living with HIV/AIDS globally.